HMPL-013: all 109 studies that test it
Page 1 of 2. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerRecruitingNCT07888309Phase 2
- A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingNCT07819019Phase 2
- Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingNCT07724223Phase 2
- Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07689292Phase 2
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingNCT07622550Phase 2
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Not applicable
- Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)Not yet recruitingNCT07510932Phase 2
- FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingNCT07446465Phase 4
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingNCT07392346Phase 2
- Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingNCT07362836Phase 3
- Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric AdenocarcinomaRecruitingNCT07270991Phase 3
- Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingNCT07261709Phase 2
- A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above TreatmentNot yet recruitingNCT07229872Phase 2
- Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial CancerNot yet recruitingNCT07170982Phase 2
- Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal CancerNot yet recruitingNCT07150403Phase 2
- Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal CancerRecruitingNCT07130903Phase 2
- Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT07124858Not applicable
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07051785Phase 2
- Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal CancerRecruitingNCT07042685Phase 2
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingNCT07011576Phase 2
- A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
- Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Phase 2
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Phase 1/2
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesRecruitingNCT06856837Phase 2
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingNCT06791083Phase 2
- A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRGRecruitingNCT06774222Phase 2
- A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.Not yet recruitingNCT06746545Phase 2
- Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingNCT06685276Phase 2
- Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
- Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.RecruitingNCT06613113Not applicable
- Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerRecruitingNCT06584032Phase 3
- A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal CancerRecruitingNCT06562543Phase 4
- ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingNCT06543836Phase 2
- Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingNCT06484153Phase 2
- Fruquintinib After ICIs Treatment in Unresectable Hepatocellular CarcinomaRecruitingNCT06446154Phase 2
- Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
- Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRecruitingNCT06317298Not applicable
- Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label StudyRecruitingNCT06234007Phase 2
- A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
- Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNCT06168786Phase 2
- Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal CancerRecruitingNCT06148402Phase 2
- Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal CancerRecruitingNCT06118762Phase 4
- Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced CancerNot yet recruitingNCT06094868Phase 2
- Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyRecruitingNCT06018714Phase 2
- Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRCRecruitingNCT06010888Phase 2
- Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
- A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingNCT05954429Phase 2
- Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric CancerNot yet recruitingNCT05914610Phase 3
- Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
- Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyRecruitingNCT05721651Phase 2
- Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric CancerNot yet recruitingNCT05643677Phase 2
- The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingNCT05634590Phase 2
- The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerRecruitingNCT05555901Phase 2
- Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal CancerRecruitingNCT05522738Phase 1/2
- Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line ChemotherapyNot yet recruitingNCT05451719Phase 2
- Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsCompletedNCT04716634Phase 2Results posted
- A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
- A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3Results posted
- A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1Results posted
- Study of Fruquintinib in Patients With Metastatic Colorectal CancerCompletedNCT02196688Phase 2Results posted
- A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyActive, not recruitingNCT07136077Phase 2
- Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRCStatus unknownNCT06427005Phase 2
- Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical TrialActive, not recruitingNCT06356597Phase 2
- Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanActive, not recruitingNCT06199973Phase 3
- A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
- Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05831891Phase 2
- Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric CancerActive, not recruitingNCT05795296Phase 2
- Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRTStatus unknownNCT05763927Phase 2
- Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal CancerWithdrawnNCT05690035Phase 2
- Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaActive, not recruitingNCT05625737Phase 2
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
- Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal CancerStatus unknownNCT05447715Phase 2
- Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
- Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line TherapyStatus unknownNCT05406206Phase 2
- Fruquintinib DDI Study With P-gp and BCRP SubstratesCompletedNCT05368805Phase 1
- Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRCStatus unknownNCT05292417Phase 2
- FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
- A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic CancerStatus unknownNCT05257122Phase 2
- Fruquintinib Hepatic Impairment StudyCompletedNCT05216367Phase 1
- Fruquintinib Renal Impairment StudyCompletedNCT05216354Phase 1
- Fruquintinib in the Treatment of Soft Tissue SarcomaStatus unknownNCT05142631Phase 2
- A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）CompletedNCT05025631Phase 2
- Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerStatus unknownNCT05016869Phase 1/2
- Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCStatus unknownNCT05004831Phase 2
- Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
- The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)Status unknownNCT04948034Phase 2
- A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous ChemotherapyStatus unknownNCT04866108Phase 2
- Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerStatus unknownNCT04733963Phase 2
- Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT04695470Phase 2
- Fruquintinib Food Effect and Proton Pump Inhibitor StudyCompletedNCT04645940Phase 1
- Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal CancerStatus unknownNCT04582981Phase 2
- Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerStatus unknownNCT04296019Phase 2
- Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerStatus unknownNCT04179084Phase 2
- Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaStatus unknownNCT04156958Phase 2
- Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal CancerStatus unknownNCT03977090Phase 1
- Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibStatus unknownNCT03976856Phase 1
- : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsCompletedNCT03903705Phase 1/2
- Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLCWithdrawnNCT03684967Phase 2
- A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)CompletedNCT03223376Phase 3